A Proposal for a Scoring System for Hemoglobinuria Following Ethanolamine Oleate Sclerotherapy in Children with Venous Malformations

jpedsurg.org

Ethanolamine oleate (EO) is a sclerosing agent commonly used to treat slow-flow vascular malformations (SFVMs). Macroscopic hemoglobinuria is the most frequent complication of EO sclerotherapy and may occasionally progress to acute renal failure. Because EO was originally developed for adult esophageal and gastric varices, data on its pediatric use remain limited. This study aimed to identify risk factors for macroscopic hemoglobinuria and to develop a practical scoring system to support the safe use of EO in children.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Mar 2026 · 1 min read

In brief

This study develops a scoring system to predict hemoglobinuria risk in pediatric patients undergoing ethanolamine oleate sclerotherapy for slow-flow vascular malformations. The research addresses a critical safety gap, as EO was originally designed for adult use and can cause renal complications in children.

Macroscopic hemoglobinuria is the most common complication of ethanolamine oleate sclerotherapy in pediatric venous malformations.
EO sclerotherapy-induced hemoglobinuria can progress to acute renal failure in some cases.
Limited pediatric safety data exists for EO since it was originally developed for adult variceal treatment.
A scoring system can help identify children at higher risk for hemoglobinuria after EO sclerotherapy.
Risk stratification tools are needed to improve the safety profile of EO use in pediatric vascular malformation treatment.

Written by the GCMD Library team from the article.

Read it at the source ↗